Psychedelic therapy in depression and substance use disorders
European Journal of Neuroscience May 21, 2024 Nur Damla Korkmaz, Ugur Cikrikcili, Merve Akan et al. 19 citations
Classical psychedelics such as psilocybin, LSD, and mescaline alter perception, emotion, and cognition by activating serotonin 5-HT2A receptors. After early research was halted in 1967 due to legal restrictions, studies resumed in the 1990s. Psilocybin-assisted psychotherapy has shown promise for treating anxiety and depression in cancer patients, as well as treatment-resistant depression and substance addictions. The article discusses the historical development, therapeutic applications, and ethical considerations of psychedelic therapy for depression, trauma disorders, and substance use disorders.